Chemistry:Odronextamab

From HandWiki
Odronextamab
Monoclonal antibody
Type?
Clinical data
Other namesREGN1979; REGN-1979
ATC code
  • None
Identifiers
CAS Number
UNII

Odronextamab (REGN1979) is a CD20 x CD3 bispecific monoclonal antibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma.[1][2][3][4]

References

  1. Wei, Joyce; Montalvo-Ortiz, Welby; Yu, Lola; Krasco, Amanda; Olson, Kara; Rizvi, Sahar; Fiaschi, Nathalie; Coetzee, Sandra et al. (9 November 2022). "CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models". Science Translational Medicine 14 (670): eabn1082. doi:10.1126/scitranslmed.abn1082. PMID 36350988. 
  2. Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; O'Brien, Susan M et al. (May 2022). "Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial". The Lancet Haematology 9 (5): e327–e339. doi:10.1016/S2352-3026(22)00072-2. PMID 35366963. 
  3. Bannerji, Rajat; Allan, John N.; Arnason, Jon E.; Brown, Jennifer R.; Advani, Ranjana; Ansell, Stephen M.; O'Brien, Susan M.; Duell, Johannes et al. (5 November 2020). "Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy". Blood 136 (Supplement 1): 42–43. doi:10.1182/blood-2020-136659. 
  4. Kim, Tae Min; Alonso, Arancha; Prince, Miles; Taszner, Michal; Cho, Seok-Goo; Stevens, Don A.; Poon, Michelle; Lim, Francesca et al. (5 November 2020). "A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Blood 136 (Supplement 1): 28–29. doi:10.1182/blood-2020-136344.